Screener
Bicara Therapeutics BCAX Total Current Assets
Total Current Assets at other companies
Other financials
Where this comes from
Reported directly by Bicara Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AssetsCurrent.
The source filing: Bicara Therapeutics’s 10-Q, filed May 11, 2026.
- Filed
- May 11, 2026, 4:03 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-033429
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Cash and cash equivalents | $323,462 | $96,685 |
| Prepaid expenses and other assets | 5,162 | 7,252 |
| Marketable securities | 216,291 | 318,116 |
| Total current assets | 544,915 | 422,053 |
| Property and equipment, net | 346 | 330 |
| Right of use asset – operating lease | 1,428 | 1,701 |
| Other assets | 6,910 | 6,910 |
| Total assets | $553,599 | $430,994 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Bicara Therapeutics's total current assets?
- Bicara Therapeutics (BCAX) reported total current assets of $544.92M in Q1 2026.
- How has Bicara Therapeutics's total current assets changed year-over-year?
- Bicara Therapeutics's total current assets increased by 15.8% year-over-year, from $470.75M to $544.92M.
- What is the long-term trend for Bicara Therapeutics's total current assets?
- Over 2 years (2023 to 2025), Bicara Therapeutics's total current assets has grown at a 35.1% compound annual growth rate (CAGR), from $231.07M to $422.05M.
- What does total current assets mean?
- The sum of all assets expected to be converted to cash or consumed within one year — cash, receivables, inventory, and prepaid expenses.
Ask your AI about Bicara Therapeutics's total current assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude